Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Nov 3:15:480-4.
doi: 10.12659/AJCR.891194.

Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib

Nobuhiro Kanaji  1 , Akira Tadokoro  1 , Naoki Watanabe  1 , Takuya Inoue  1 , Tomoya Ishii  1 , Hiroaki Dobashi  1 , Shuji Bandoh  1
Affiliations
Case Reports

Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib

Nobuhiro Kanaji et al. Am J Case Rep. .

Abstract

Background: Increases in tumor marker concentrations usually suggest disease progression.

Case report: We here describe on 3 patients with non-small cell lung cancer whose serum concentrations of CYFRA21-1 increased in spite of successful treatment with crizotinib. Discontinuation of crizotinib resulted in a rapid decrease in serum CYFRA21-1 concentrations in all cases. In 1 patient with progressive disease, in spite of increasing the dose of crizotinib, CYFRA21-1 concentrations decreased.

Conclusions: Crizotinib can induce increases in CYFRA21-1 concentration without disease progression. Pulmonologists and oncologists should be aware of this novel phenomenon, and focus on interpretation of CYFRA21-1 concentrations in monitoring tumor response to crizotinib treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Chest CT of Case 1 before (A) and after (B) crizotinib treatment. Arrows show mediastinal lymph nodes.
Figure 2.
Figure 2.
Chest CT of Case 2 before (A) and after (B) crizotinib treatment. Arrows show primary lesion and arrowheads show pleural dissemination.
Figure 3.
Figure 3.
Abdominal CT of Case 3 before (A) and after (B) crizotinib treatment. Arrows show liver metastasis and arrowhead shows an adrenal metastasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ono A, Takahashi T, Mori K, et al. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer. 2013;13:354. - PMC - PubMed
    1. Park SY, Lee JG, Kim J, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer. 2013;79:156–60. - PubMed
    1. Cedrés S, Nuñez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC) Clin Lung Cancer. 2011;12:172–79. - PubMed
    1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–19. - PMC - PubMed
    1. Yang L, Chen X, Li Y, et al. Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer. Exp Ther Med. 2012;4:243–48. - PMC - PubMed

Publication types

MeSH terms